Back to Main

Faculty Detail    
Name SHUKO HARADA
 
Campus Address NP 3540 Zip 6823
Phone  205-996-5848
E-mail  sharada@uabmc.edu
Other websites
     

Education
Medical School  University of Tokyo Faculty of Medicine, Tokyo, Japan    1985  M.D. 

Certifications
American Board of Pathology, Anatomic and Clinical  2008 
Molecular Genetic Pathology  2011 


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pathology   Anatomic Pathology Associate Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Associate Professor

Biographical Sketch 
Dr. Harada received her medical degree from the University of Tokyo Faculty of Medicine and completed her residency training for Internal Medicine, worked as an internist in Endocrinology and Metabolism in Tokyo, Japan. She moved to USA and conducted research on insulin signal transduction and gene regulation at University of Pennsylvania, a part of which as a research faculty. She completed her residency at Drexel University College of Medicine followed by surgical pathology and molecular genetic pathology fellowship at University of Pennsylvania and Johns Hopkins University, respectively. She joined the faculty at UAB in August, 2011. Dr. Harada is board certified in Anatomic and Clinical Pathology as well as Molecular Genetic Pathology. Currently she is Head of Molecular Diagnostic Laboratory, which offers wide variety of molecular and genomic testing for infectious diseases and oncology including next generation sequencing analysis. She has particular interests in precision medicine in oncology and pharmacogenomics, and a member of Precision Medicine Institute and Comprehensive Cancer Center.

Society Memberships
Organization Name Position Held Org Link
AMP (Association for Molecular Pathology)  member   
Association of Clinical Scientists (ACS)  fellow member   
College of American Pathologists   fellow member   
United States and Canadian Academy of Pathology  member   



Research/Clinical Interest
Title
Molecular Profiling of Breast ductal carcinoma in situ; Implementation of next generation sequencing into precision medicine
Description
My research interests are following; 1. Clinical implementation of next generation sequencing of cancer and correlation with clinical status 2. Molecular profiling and discovery of molecular markers in ductal carcinoma in-situ of breast 3. Implementation of genotype guided decision making into clinical workflow

Selected Publications 
Publication PUBMEDID
Stevens TM, Morlote D, Swensen J, Ellis M, Harada S, Spencer S, Prieto-Granada CN, Folpe AL,. Gatalica Z. Spindle epithelial tumor with thymus-like differentiation (SETTLE): a next-generation sequencing study. Head and Neck Pathology. 2018 May 7. doi: 10.1007/s12105-018-0927-1. [Epub ahead of print]   29736783 
Zhou Y, Armstead AR, Coshatt GM, Limdi NA, Harada S. Comparison of two point-of-care CYP2C19 genotyping assays for genotype-guided antiplatelet therapy. Ann Clin & Lab Sci. 47:217-222, 2017  29263048 
Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 11(2):181-191, 2018.  29102571; PMC5775044 
Dussaq A, Soni A, Willey CD, Park SL, Harada S. HCV Genie: A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus (HCV) Genotype Line Probe Assay Version 2.0. J Pathol Informatics. 8:41. doi: 10.4103/jpi.jpi_44_17. eCollection 2017.  29114435; PMC5653960 
Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin M, Nabell L, Nabors LB, Roth KA, Partridge EE, Siegal GP, Yang ES. Implementation and utilization of the molecular tumor board to guide precision medicine. Oncotarget 6:57845-57854, 2017  28636540 
Harada S, Silzle E, Lin M-T, Gocke CD. Detection of Chromosomal Translocation in Hematologic Malignancy by a Novel DNA-based Looped Ligation Assay (LOLA) Clin Chem. 63:1278-1287, 2017.   28515100 
Siniard RC and Harada S. Immunogenomics: Using genomics to personalize cancer immunotherapy [REVIEW]. Virchows Arch. 471(2):209-219, 2017.  28528510 
Harada S, Zhou Y, Duncan S, Armstead AR, Coshatt GM, Dillon C, Brott BC, Willig J, Alsip JA, Hillegass WB, Limdi NA. Precision medicine at the University of Alabama at Birmingham: Laying the foundational process through implementation of genotype-guided antiplatelet therapy. Clin Pharmacol Ther. 102:493-501, 2017.  2812392 
Agosto-Arroyo E, Coshatt GM, Winokur TS, Harada S, Park SL. Alchemy: A web 2.0 real-time quality assurance platform for molecular testing. J Pathol Informatics. 8:18. doi: 10.4103/jpi.jpi_69_16. eCollection 2017.  28480121 
Jinawath N, Shiao, M-S, Norris A, Murphy K, Klein AP, Yonescu R, Iacabuzzio-Donahue C, Meeker A, Jinawath A, Yeo CJ, Eshleman JR, Hruban RH, Brody J, Griffin GA, Harada S. Alteration of type II classical cadherin Cadherin-10 (CDH10) is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes Cancer 56:427-435, 2017.   2812395 
Agosto-Arroyo E, Isayeva T, Almeida JS, Harada S. Molecular profiling of breast ductal carcinoma in situ (DCIS) - Gene expression signature of ERBB2 positive DCIS. Cancer Control. 24(1):102-110, 2017  28178722 
Ping Z, Siegal GP, Harada S, Eltoum, IA, Youssef M, Shen T, He J, Huang Y, Chen D, Li Y, Bland KI, Chang HR, Shen D. ERBB2 mutation is associated with a worse prognosis in the patients with CDH1 altered invasive lobular cancer of the breast. Oncotarget 7(49):80655-80663, 2016.   27811364 
Duncan VE, Harada S, Stevens TM. Primary colon adenosquamous carcinoma in a patient with Lynch syndrome: A new histologic subtype associated with microsatellite instability? International Journal of Surgical Pathology 24:653-666, 2016.   27422471 
Harada S. Chapter 10 DNA and RNA extractions from mammalian samples. A book chapter in “Sample Preparation Techniques for Soil, Plant, and Animal Samples.” Ed. Micic M (by invitation). Springer, 2016. pp 125-138.   
Wu X, Lee JW, Peker D, Spitzer SG, Laser J, Reddy V, Harada S. Is low positive JAK2 V617F mutation test result clinically significant? Appl Immunohistochem Mol Morphol 24:589-594, 2016  26371429 
McIntosh ER, Harada S, Drwiega J, Brandwein-Gensler MS, Gordetsky J. Frozen Section: Guiding the Hands of Surgeons? Ann Diag Pathol. 19:326-329, 2015   26320052 
Harada S, Agosto-Arroyo E, Levesque JA, Alston E, Janowski K, Coshatt G, Eltoum IA. Poor Cell Block Adequacy Rate for Molecular Testing Improved with the Addition of Diff Quik Stained Smears: Need for Better Cell Block Processing. Cancer Cytopathol 123:480-487, 2015   25955105 
Agosto-Arroyo E, Isayeva T, Almeida JS, Harada S. Molecular Pathology: SY18-1 MOLECULAR PROFILING OF BREAST DUCTAL CARCINOMA IN-SITU. Pathology. 2014 Oct;46 Suppl 2:S29  25188123 
Harada S, Wei, S, Siegal GP. Molecular Pathology of Osteosarcoma. A book chapter in “Bone Cancer – Primary bone cancers and bone metastases.” second edition, Ed Dominique Heymann. Academic Press 2015.    
Cui C, Harada S, Shen D, Siegal GP, Wei S. The utility of Phosphohistone H3 in breast cancer grading. Appl Immunohistochem Mol Morphol. 23:689-695, 2015   25611243 
Peker D, Parekh V, Paluri R, Deal T, Borate U, Harada S, Agosto-Arroyo E, Reddy V. Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: A single institution experience. International J of Hematol.100(5):457-463, 2014   25209604 
Liu X, Harada S. RNA isolation from human samples. Curr Protoc Mol Biol. Chapter 4:Unit 4.16, 2013   23821441 
Liu X, Harada S. DNA isolation from human samples. Curr Protoc Mol Biol. Chapter 2:Unit 2.14, 2013   23547013 
Lin MT, Tseng LH, Rich RG, Hafez MJ, Harada S, Murphy KM, Eshleman JR, Gocke CD. Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations. J Mol Diagn. 13:85-92, 2011.  3069866 
Chen G, Olson MT, O’Neill A, Norris A, Beierl K, Harada S, Debeljak M, Rivera-Roman K, Finley S, Stafford A, Gocke CD, Lin M-T, Eshleman JR. A virtual program generator to resolve complex pyrosequencing results. J Mol Diag 14(2): 149-159, 2012.   22316529 
Harada S, Henderson LB, Eshleman JR, Gocke CD, Burger P, Griffin CA, Batista DA. Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue superior results compared with microsatellite analysis. J Mol Diagn. 13:541-548, 2011.  21726663 
Harada S, Mick R, Roses RE, Graves H, Niu H, Sharma A, Schueller JE, Nisenbaum H, Czerniecki BJ, Zhang PJ. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol. 104:458-465, 2011.  21557226 
Munfus-McCray D, Harada S, Adams C, Askin F, Clark D, Gabrielson E, Li QK. EGFR and KRAS mutations in metastatic lung adenocarcinomas. Hum Pathol. 42:1447-1453, 2011.  21497370 
Harada S, Korf BR. Overview of molecular genetic diagnosis. Curr Protoc Hum Genet. Chapter 9:Unit 9.1, 2013.  23315929 
Harada S, Sepulveda AR. Chapter 5. Molecular mechanisms and pathology of gastric carcinogenesis: sporadic cancers. A book chapter in “Molecular Pathology of Neoplastic Gastrointestinal Diseases.” Ed. Sepulveda AR and Lynch JP. Springer, 2013.   
Wolff B, Harada S. Molecular pathology and molecular markers of ductal carcinoma in-situ. Current Cancer Therapy Reviews, 8(3), 197-204, 2012.   
Lin YJ, Harada S, Loten EG, Smith RM, Jarett L . Nuclear insulin is associated with g33 and c-fos transcription in trypsin-treated H35 hepatoma cells. Proc Nat Acad Sci USA 89: 9691-9694, 1992.   1409684 
Harada S, Loten EG, Smith RM, Jarett L. Non-receptor mediated nuclear accumulation of insulin in H35 rat hepatoma cells. J Cellular Physiol. 153: 607-613, 1992   1447321 
Harada S, Smith JA, Smith RM, Jarett L. Inhibition of insulin degrading enzyme (IDE) increases translocation of insulin to the nucleus in H35 rat hepatoma cells: Evidence of a cytosolic pathway. Endocrinology 132: 2293-2298, 1993.   8504733 
Harada S, Smith RM, Jarett L. The paradoxical effect of 1,10-phenanthroline on nuclear accumulation of insulin and gene expression stimulated by insulin. DNA and Cell Biol. 13: 487-493, 1994.  8024692 
Jarett L, Harada S, Lee Y-H, Smith JA, Shah N, Zhang S, Smith RM. Insulin endocytosis and other alternative pathways in the insulin signal transduction network. Antibody, Immunoconjugates, and Radiopharmaceuticals 8: 251-259, 1995.    
Shah N, Zhang S, Harada S, Smith RM, Jarett L. Electron microscopic demonstration of insulin translocation to the cytoplasm and nuclei of intact H35 hepatoma cells using covalently linked Nanogold-insulin. Endocrinology 136: 2825-2835, 1995.  7789307 
Harada S, Smith RM, Smith JA, Shah N, Jarett L. Demonstration of specific insulin binding to cytosolic proteins in H35 hepatoma cells, rat liver and skeletal muscle. Biochemical J. 306: 21-28, 1995.  7592888 
Harada S, Smith RM, Smith JA, Shah N, Hu D-Q, Jarett L. Insulin-induced egr-1 expression in Chinese hamster ovary cells is insulin receptor and insulin receptor substrate-1 phosphorylation independent: Evidence of an alternative signal transduction pathway. J Biol Chem. 270: 26632-26638, 1995.   7592888 
Harada S, Smith RM, Hu D-Q, Jarett L. Dexamethasone inhibits insulin binding to insulin-degrading enzyme and cytosolic insulin-binding protein p82. Biochem Biophys Res Commun. 218: 154-158, 1996.   8573122 
Lee Y-H, Harada S, Smith RM, Friedman R, Jarett L. The expression of and insulin binding to cellular thyroid hormone binding protein, but not insulin degrading enzyme, is increased during 3T3-L1 adipocytes differentiation. Biochem Biophys Res Commun. 222: 839-843, 1996.   8651932 
Harada S, Smith RM, Smith JA, White MF, Jarett L. Insulin-induced egr-1 and c-fos expression in 32D cells requires insulin receptor, Shc and mitogen activated protein kinase, but not insulin receptor substrate-1 and phosphatidyl inositol 3-kinase activation. J Biol Chem. 271: 30222-30226, 1996.  8939974 
Smith RM, Harada S, Jarett L. Roles of insulin internalization and other signaling pathways in the pleiotropic effects of insulin. Intern Rec Cytol. 173: 243-280, 1997  9127955 
Smith RM, Harada S, Smith JA, Zhang S, Jarett L. Insulin-induced protein tyrosine phosphorylation cascade and signaling molecules are enriched in membrane caveolae in hepatoma cells. Cellular Signalling 10: 355-362, 1998  9692679 
Harada S, Smith RM, Jarett L. Mechanisms of nuclear translocation of insulin. Cell Biochem Biophy. 30 (3): 307-319, 1999.  10736753 
Solow BT, Derrien A, Smith JA, Jarett L, Harada S. Angiotensin II inhibits insulin-induced egr-1 expression in mesangial cells but not in glomerular endothelial cells. Arch Biochem Biophys. 370: 308-313, 1999.  10510289 
Solow BT, Harada S, Goldstein BJ, Smith JA, White MF, Jarett L. Differential modulation of the tyrosine phosphorylation state of the insulin receptor by IRS proteins. Mol Endocrinol. 13: 1784-1798, 1999  10517679 
Harada S, Esch GL, Holgado-Madruga M, Wong AJ. Grb-2 associated binder-1 (Gab1) is involved in insulin-induced egr-1 gene expression through its PI3’-kinase binding site. DNA and Cell Biol. 20: 223-229, 2001.   11403719 
Hasan R, Phukan S, Harada S. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 23: 988-993, 2003   12689920 
Harada S, Kalla H, Balasubramanian M, Brodsky I, Gladstone D, Hou JS. Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen. Ann Diagnostic Pathol, 12(3): 212-216, 2008  18486899 

Keywords
molecular pathology, breast pathology, precision medicine